Exercise has emerged as an effective treatment for depression, rivaling medication and psychotherapy in its ability to reduce symptoms. Both aerobic and resistance training provide mental health benefits, with a combination of the two being optimal. However, exercise is vastly underutilized and more research is needed to uncover the mechanisms behind its antidepressant effects. Highlights: …
Ketamine causes rapid and sustained antidepressant effects that last longer than its presence in the body. This is due to ketamine getting trapped and accumulating in NMDA receptors, causing prolonged neural inhibition. Manipulating brain activity can shorten or extend ketamine’s effects. Highlights: Ketamine continues blocking NMDA receptors for 24 hours despite rapid elimination from plasma …
The NLRP3 inflammasome stands at the crossroads of immune response and mental health, playing a pivotal role in the inflammatory processes implicated in depression. Researchers are exploring the intricate relationship between NLRP3 activation and depressive disorders, highlighting the potential for innovative treatments targeting this complex molecular pathway. Highlights: NLRP3 Inflammasome Activation: NLRP3, a component of …
Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …
Depression is a growing public health concern, but nutrition may offer a pathway for prevention and treatment. A new research study identified the most nutrient-dense foods for brain health to inform dietary recommendations. Key Facts: 12 nutrients have evidence supporting a role in preventing and treating depression, including omega-3s, B vitamins, minerals like magnesium, and …
Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …
Researchers have uncovered a critical role for the metabolic enzyme acetyl-CoA synthetase short-chain family member 2 (ACSS2) in depression, identifying it as a novel target for rapid-acting and long-lasting antidepressant therapies. Findings show ACSS2 regulates both brain-derived neurotrophic factor (BDNF) levels to improve synaptic plasticity and serotonin synthesis through tryptophan hydroxylase 2 (TPH2) to mediate …